Skip to main content

Advertisement

SpringerLink
Log in

Off-target toxicity: Risks associated with adrenal corticoid activation in ILLUMINATE

  • Clinical Trials Report
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rosenson RS: Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J 2006, 151:556–563.

    Article  PubMed  CAS  Google Scholar 

  2. Barter P, Gotto AM, LaRosa JC, et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301–1310.

    Article  PubMed  CAS  Google Scholar 

  3. Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505–1515.

    Article  PubMed  CAS  Google Scholar 

  4. Davidson MH, McKenney JM, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006, 48:1774–1781.

    Article  PubMed  CAS  Google Scholar 

  5. McKenney JM, Davidson MH, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006, 48:1782–1790.

    Article  PubMed  CAS  Google Scholar 

  6. Pfizer Inc.: In interests of patients safety, Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities. Pfizer news release. December 2, 2006. Available at http://www.fda.gov/bbs/topics/NREWS/2006/NEW0154.html. Accessed October 30, 2007.

  7. Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.

    Article  PubMed  CAS  Google Scholar 

  8. Blood Pressure Lowering Trialists’ Collaboration: Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003, 362:1527–1535.

    Article  Google Scholar 

  9. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.

    Article  PubMed  CAS  Google Scholar 

  10. Forrest MJ, Sparrow CP: Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levels. Paper presented at American Heart Association Scientific Sessions. Orlando, FL; November 4–7, 2007.

  11. Keidar S, Kaplan M, Pavlotzky E, et al.: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213–2220.

    Article  PubMed  CAS  Google Scholar 

  12. Rajagopalan S, Duquaine D, King S, et al.: Mineralcorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212–2221.

    Article  PubMed  CAS  Google Scholar 

  13. Takai S, Jin D, Muramatsu M, et al.: Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005, 46:1135–1139.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert S. Rosenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenson, R.S. Off-target toxicity: Risks associated with adrenal corticoid activation in ILLUMINATE. Curr Atheroscler Rep 10, 227–229 (2008). https://doi.org/10.1007/s11883-008-0035-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0035-x

Keywords

Search

Navigation